SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...
To investigate their recruitment, Gata6-iCreER mice were crossed with Cd45-Dre and R26-tdT mice, enabling specific lineage tracing of cavity macrophages. Flow cytometry and immunofluorescence ...
Using localized force-distance curves from AFM, a deep neural network was trained and biologically validated to predict and accurately distinguish macrophage polarization states, including complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results